FivepHusion
Melbourne, Australia· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Australianbiotech developing a pH‑optimized 5‑FU/leucovorin combo to enhance safety and efficacy across solid and paediatric brain cancers.
Oncology
Technology Platform
All‑in‑one pH‑optimized formulation of 5‑FU and leucovorin for systemic delivery, plus the ResectAssist™ platform for localized drug deposition into solid tumours.
Opportunities
Successful Phase III data could enable market entry as a premium 5‑FU alternative and open licensing or partnership deals for the ResectAssist™ platform.
Risk Factors
Clinical development delays, regulatory hurdles, and the need for substantial financing to advance to commercial stage pose significant risks.
Competitive Landscape
Deflexifol™ differentiates from generic 5‑FU by improved tolerability and efficacy, while ResectAssist™ offers a novel localized delivery approach not widely available from competitors.